Anti-COVID-19 2-DG drug developed by DRDO was first studied by Patanjali, claims Acharya Balkrishna

New Delhi: 2-deoxy-D-glucose (2-DG), the anti-COVID-19 drug that

has been developed by Defence Research and Development Organization (DRDO)

and been given an emergency use nod by Drugs Controller General of India’s (DCGI),

was first studied by Patanjali researchers, claimed Acharya Balkrishna.

Also Read Story

New Delhi NEET paper solver gang busted; four arrested

Bibhav Kumar arrested in Swati Maliwal assault case

India, Pakistan advise students in Kyrgyzstan to stay indoors amid mob violence

Delhi Police record Swati Maliwal’s 164 CrPC statement